Galectin Therapeutics posts results for belapectin hepatic impairment PK study

Galectin Therapeutics had one notable regulatory update in the week, a results posting for a completed early-phase pharmacokinetics study.

• Belapectin (GR-MD-02), a Phase 1 study in subjects with hepatic impairment, is listed as completed, with primary completion and study completion both dated 2022-03-09¹. The study, sponsored by Galectin Therapeutics Inc., had an enrollment of 38 participants¹ and was designed to determine the effect of hepatic impairment on the PK, safety, and tolerability of a single IV dose of belapectin compared to matched healthy subjects with normal hepatic function.¹ Results were first posted on 2026-07-14¹, the same date as the last update.